Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
27.90
-2.07 (-6.91%)
At close: Dec 20, 2024, 4:00 PM
27.89
-0.01 (-0.04%)
After-hours: Dec 20, 2024, 7:10 PM EST
Structure Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
93
Market Cap
1.60B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGPCR News
- 4 days ago - Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity - GlobeNewsWire
- 5 weeks ago - Structure Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity - GlobeNewsWire
- 2 months ago - Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients - Seeking Alpha
- 3 months ago - Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. - GlobeNewsWire
- 4 months ago - Structure Therapeutics Appoints Angus C. Russell to Board of Directors - GlobeNewsWire
- 4 months ago - Structure Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say - Market Watch